
Divi's Laboratories Ltd
NSE:DIVISLAB

Operating Margin
Divi's Laboratories Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
IN |
![]() |
Divi's Laboratories Ltd
NSE:DIVISLAB
|
1.8T INR |
28%
|
|
US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
15%
|
|
US |
![]() |
Thermo Fisher Scientific Inc
NYSE:TMO
|
180.1B USD |
18%
|
|
US |
![]() |
Danaher Corp
NYSE:DHR
|
147.2B USD |
20%
|
|
KR |
![]() |
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
32%
|
|
CH |
![]() |
Lonza Group AG
SIX:LONN
|
39.7B CHF |
18%
|
|
US |
![]() |
IQVIA Holdings Inc
NYSE:IQV
|
34.4B USD |
15%
|
|
US |
![]() |
Agilent Technologies Inc
NYSE:A
|
34.2B USD |
23%
|
|
CN |
![]() |
WuXi AppTec Co Ltd
SSE:603259
|
242.8B CNY |
27%
|
|
US |
![]() |
Mettler-Toledo International Inc
NYSE:MTD
|
26.1B USD |
29%
|
|
FR |
![]() |
Sartorius Stedim Biotech SA
PAR:DIM
|
17B EUR |
14%
|
Divi's Laboratories Ltd
Glance View
Divi's Laboratories Ltd. has carved an enviable niche for itself in the global pharmaceutical industry, with its origins tracing back to 1990 in Hyderabad, India. With a steadfast focus on research and development, the company stands as a formidable force in the Active Pharmaceutical Ingredients (APIs) and Intermediates manufacturing sector. Its strategy hinges on two complementary business segments: generic APIs and custom synthesis of APIs and intermediates. By catering to a broad spectrum of therapeutic areas, from cardiovascular ailments to pain management, Divi's capitalizes on economies of scale and technological innovation to produce cost-effective, high-quality pharmaceutical products. This strategy not only aligns with the company’s expertise in process development and chemical synthesis but also positions it as a key supplier to major pharmaceutical companies worldwide, providing a significant portion of their API requirements. The crux of Divi's financial engine lies in its custom synthesis segment, where it forms strategic alliances with global pharmaceutical giants, offering end-to-end solutions from drug discovery to commercialization. This vertical is fueled by long-term contracts that bolster the company’s revenue visibility and profitability. Meanwhile, the generic APIs segment benefits from the rising global demand for affordable healthcare solutions, particularly in emerging markets. Divi’s Laboratories leverages its state-of-the-art manufacturing facilities, which are compliant with international regulatory standards, to ensure efficient production cycles and maintain a consistent supply chain. Through its blend of innovative R&D, a robust manufacturing backbone, and strategic partnerships, Divi's Laboratories adeptly navigates the complexities of the pharmaceutical industry, making it a stalwart in the sector's supply chain ecosystem.

See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Divi's Laboratories Ltd's most recent financial statements, the company has Operating Margin of 28%.